key: cord-0802553-fpzvd2xz authors: Wu, Canhao; Xu, Qin; Wang, Huiyuan; Tu, Bin; Zeng, Jiaxin; Zhao, Pengfei; Shi, Mingjie; Qiu, Hong; Huang, Yongzhuo title: Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles date: 2021-09-09 journal: Acta Pharm Sin B DOI: 10.1016/j.apsb.2021.09.004 sha: 8e82ae3e577a868af81dcc916a1c87808500d0ba doc_id: 802553 cord_uid: fpzvd2xz The spread of coronavirus disease 2019 (COVID-19) throughout the world has resulted in stressful healthcare burdens and global health crises. Developing an effective measure to protect people from infection is an urgent need. The blockage of interaction between angiotensin-converting enzyme 2 (ACE2) and S protein is considered an essential target for anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) drugs. A full-length ACE2 protein could be a potential drug to block early entry of SARS-CoV-2 into host cells. In this study, a therapeutic strategy was developed by using extracellular vesicles (EVs) with decoy receptor ACE2 for neutralization of SARS-CoV-2. The EVs embedded with engineered ACE2 (EVs-ACE2) were prepared; the EVs-ACE2 were derived from an engineered cell line with stable ACE2 expression. The potential effect of the EVs-ACE2 on anti-SARS-CoV-2 was demonstrated by both in vitro and in vivo neutralization experiments using the pseudovirus with the S protein (S-pseudovirus). EVs-ACE2 can inhibit the infection of S-pseudovirus in various cells, and importantly, the mice treated with intranasal administration of EVs-ACE2 can suppress the entry of S-pseudovirus into the mucosal epithelium. Therefore, the intranasal EVs-ACE2 could be a preventive medicine to protect from SARS-CoV-2 infection. This EVs-based strategy offers a potential route to COVID-19 drug development. sequela rate is found to be very high in the infected patients discharged after hospitalization 2, 3 . Considering the limited availability and accessibility of COVID-19 vaccination, as well as the increasing incidence of immune escape after vaccination, the development of anti-SARS-CoV-2 therapeutics is still a pressing need for the world. However, there are currently no specific antiviral drugs for SARS-CoV-2 despite great effort and input from the scientific community. For example, an initial randomized, double-blinded trial of Remdesivir in China showed no substantial benefit to patients 4 . Several repurposed drugs (e.g., chloroquine and anti-IL 6) have been evaluated in clinical trials, ending with little therapeutic benefit 5, 6 . The viral structural S proteins in SARS-CoV-2, which form a characteristic crown on the virion surface, govern the entry of coronavirus into host cells 7 . The interaction between angiotensin-converting enzyme 2 (ACE2) in the host cells and S proteins of SARS-CoV-2 is the essential mechanism for infection, and ACE2 serves as a major entry receptor for mediating the entry of SARS-CoV-2 into host cells 8, 9 . Further down, ACE2 was seen to be upregulated in COVID-19 patients, and therefore, the blockage of ACE2 and the S protein is considered a target for drug design 10, 11 . For instance, a recent study demonstrated that human recombinant soluble ACE2 (hrsACE2) protein can inhibit SARS-CoV-2 entry into host cells 12 . However, recombinant ACE2 exhibits a fast clearance rate, with a dose-independent terminal half-life of only 10 h reported in clinical pharmacokinetic studies 13 . The short half-life could be a huge barrier to practical use. Extracellular vesicles (EVs) are defined as cell-derived vesicles averaging 100 nm in diameter 14, 15 , and also referred to as the natural "Trojan horses" for drug delivery and therapy 16, 17 . Clinical trials based on EVs have shown positive results 18 . Because of the great promise of EVs in serving as a carrier for biomacromolecules, big pharma companies have invested heavily in the R&D of EVs 19 . In this study, EVs with genetically engineered embedded ACE2 (termed EVs-ACE2) were used as antagonists against the S protein, thereby neutralizing the S-pseudovirus and inhibiting its entry into the host cells (Fig. 1A ). complying with the animal experiment guidelines, have been approved by the Institutional Animal Care and Use Committee (IACUC) of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China. Anti-ACE2 antibody and anti-SARS-CoV-2 spike glycoprotein antibody (Abcam, Cambridge, UK); Plasmid Mini, Midi and Maxi Kits (Qiagen, Hilden, Germany); Firefly Luciferase Reporter Assay Kit (Meilunbio, Dalian, China); Human ACE2 protein (Sino Biological, Beijing, China); Hoechst 33342 (Meilunbio, Dalian, China). Prior to cell culture, FBS (fetal bovine serum) was centrifuged at 100,000×g (CP100NX ultracentrifuge, Hitachi, Tokyo, Japan) for 2 h to deplete the serumderived extracellular vesicles (EVs-free FBS). HEK293T and HEK293T-ACE2 cells, utilized for extracellular vesicle production, were cultured in Dulbecco's Modified Eagle Medium (DMEM) with 10% EVs-free FBS for 48 h. Briefly, the EVs were isolated from the cell culture medium according to the method of a previous report 20 . After three centrifugations (300×g 10 min, 2000×g 10 min, and 10,000×g 30 min) using the Heraeus Multifuge X1R (ThermoFisher, Osterode am Harz, Germany), the pellets, probably including cells, dead cells, cell debris, and large vesicles, were discarded. The supernatant was ultracentrifuged at 100,000×g for 70 min at 4°C using the CP100NX ultracentrifuge (Hitachi). The EVs thus obtained were then resuspended using PBS and ultracentrifuged again at 100,000×g for 70 min (Hitachi). The purified EVs were collected for the subsequent experiments. An NTA was performed using a Nanosight NS300 instrument (Malvern Instruments, Worcestershire, UK). For transmission electron microscopy (TEM), the EVs were dropped onto the grids for 1 min, contrasted with 1% uranyl acetate, and dried. The The freshly isolated EVs were stored at 4 °C in an EVs-free culture medium and the J o u r n a l P r e -p r o o f particle size changes in the test time frame were measured using NTA. The ACE2 expression in EVs-ACE2 was determined by the Coomassie brilliant blue method using human ACE2 protein (Sino Biological, Beijing, China) as a standard (Bio-Rad, Hercules, CA, USA). During the quantification procedure, a standard protein human ACE2 was separately loaded in 0.025, 0.5, 0.75, 1.0, and 1.5 µg to five lanes. The standard protein was used to give a standard curve of known concentration. The whole EVs-ACE2 lysate (2 and 5 µg of total protein amount) was also separately loaded to two lanes on the same gel. The content of ACE2 in each sample lane was then quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA). To generate the SARS-CoV-2 S-pseudovirus, the HEK293T cells were co-transfected The level of the S protein was analyzed using a WB analysis with Anti-SARS-CoV-2 spike glycoprotein antibody (Abcam), according to a standard procedure. The total protein concentration was measured using a standard BCA method. The median size and size distribution of the S-pseudovirus were analyzed using NTA. The cells were seeded in 12-well plates at a density of 5 × 10 5 cells per well and incubated for 24 h. The cells were then collected and the levels of ACE2 analyzed by WB with anti-ACE2 antibody (Abcam), according to a standard procedure. The total protein concentration was measured using a standard BCA method. To investigate the inhibition of pseudovirus attachment by EVs-ACE2, the cells were seeded in the 24-well plates at a density of 2.5 ×10 5 cells per well. After a 24 h culture, the S-pseudovirus (5 × 10 7 particles per well) were incubated with EVs-ACE2 or EVs-Control at 37 °C for 4 h (the ratio of pseudovirus and EVs was 1:5, based on the NTA particle quantity), followed by culture with different cells for 12 h. Cell nuclei were then stained with Hoechst 33342 for 5 min, thoroughly washed with PBS three times to perform the fluorescent imaging (CARL ZEISS). For the quantitative measurements, the cells were digested, collected, and then analyzed using a flow cytometer (NovoCyte, Agilent, Santa Clara, USA). The S-pseudovirus without EVpretreatment was used as a negative control. To investigate the inhibition effect of pseudovirus infection by EVs-ACE2, the Spseudovirus were also pretreated with the EVs-ACE2 4 h prior to adding to the cells. and 5′-GGCTGCGAAATGCCCATACT-3′, respectively. And the actin (the loading control) forward and reverse primers were 5′-GGTCATCACTATTGGCAACG-3′ and 5′-ACGGATGTCAACGTCACACT-3′, respectively. The BALB/c mice were randomly divided into three groups. At the beginning of the experiment, the mice were placed in an animal anesthesia machine (E-ZSystem, Additionally, the quantification of luciferase expression in the nasal mucosa tissues was determined by qRT-PCR. Total RNA was isolated from the nasal mucosa tissues with Trizol (Tiangen). The reverse transcription was performed using the iScriptTM gDNA Clear cDNA Synthesis Kit (Bio-Rad). The dissected nasal mucosa tissues were used to verify whether the ACE2 protein was expressed. After they were cut into pieces, 2 mL of the cell lysate was added, and they were placed on a shaker at 37 °C for digestion for 1 h. The lysate was then filtered using nylon mesh to remove the residual tissue. The total protein was determined using a BCA kit, and the samples were processed by SDS-PAGE and transferred to nitrocellulose membranes. The blots were probed with Anti-ACE2 and were visualized using a ChemiDoc MP Imaging System (Bio-Rad). The EVs-ACE2 or EVs-Control (60 μg in 20 μL PBS) were administered into the nasal cavity of the BALB/c mice, and the blood was collected via the orbital vein three days later. The serum was collected and analyzed using an automated For the hematoxylin-eosin staining, the BALB/c mice were randomly divided into three groups. The mice received PBS (the blank control), EVs-ACE2 (60 μg), and the EVs-Control (60 μg) via nasal administration. The animals were then humanely sacrificed 72 h post-administration, and the major organs (heart, liver, spleen, lung, and kidney) were collected and fixed using 4% paraformaldehyde for histopathological examination. Statistical analysis was performed using t-tests and one-way analysis of variance (ANOVA). Data were expressed as mean±standard deviation (SD). Statistically, significant difference was defined as *P<0.05, **P<0.01, and ***P<0.001. The engineered 293T cells with stable expression of full-length human ACE2 (HEK293T-ACE2) were constructed using a lentivirus. The 293T cells are an experimentally amenable, homogenous cell line that is routinely used in cell engineering 24 and as exosome donors and packaging cells 25, 26 . Moreover, the EVs derived from 293T cells have been demonstrated to be immunologically inert 27, 28 . The EVs-ACE2 were purified from the cell culture supernatants using differential ultracentrifugation. Meanwhile, the EVs derived from the HEK293T control cells without ACE2 transfection (termed EVs-Control) were also prepared. The median particle diameter of the EVs-ACE2 was 58.5 nm, and that of the EVs-Control was Transmission electronic microscopy showed the morphology of the EVs-ACE2 with a double-layer membrane (Fig. 1E) . The ACE2 expression on the EVs-ACE2 was confirmed by Western blot (WB) analysis (Fig. 1F) . The quantitative analysis of ACE2 expression in EVs-ACE2 was determined by SDS-PAGE with Coomassie Brilliant Blue staining, using human ACE2 as the standard protein (Fig. 3B) , and the ACE2 expression in EVs-ACE2 is 35 μg/mg protein (Fig. 3B) . Furthermore, the stability of the resuspended EVs after ultracentrifugation was evaluated by NTA, and the EVs remained stable in the test J o u r n a l P r e -p r o o f time frame (Fig. 1G ). S-protein pseudovirus was generated by using a lentivirus-based pseudoviral system co-packing PNL4-3.LUC.R-E, NCOV.HIS-SPIKE-FL, and PTAGRFP. The transfection efficiency of the pseudovirus was reflected by the S-protein expression, which showed a high level by the WB analysis ( Fig. 2A) . The particle size of the Spseudovirus is shown in Fig. 2B . Because pseudoviral particles could aggregate, they showed different peaks. For the pTagRFP-labeled S-protein pseudovirus, the fluorescence intensity served as an indicator of the ability of the pseudovirus to enter the cells. According to the results (Fig. 2C) , a packing ratio of 1:0.5 (w/w) between PNL4-3.LUC.R-E, NCOV.HIS-SPIKE-FL was optimal for preparing the pseudovirus. S-pseudovirus provides a useful model to safely study SARS-CoV-2 with benefits of non-replicability and tractability 21-23 . The one created in our study is characterized by three major functional components, namely, the viral envelope S protein, a tracer protein red fluorescence protein (RFP), and a reporter luciferase gene. Thus, the infection process of the S-pseudovirus can be indicated by the RFP signal and luciferase activity. The first step for a virus to infect a host cell is attachment onto the cell membrane via the viral receptors. In SARS-CoV-2, the S2 subunit of the S protein is highly conserved, and the S protein binds to the ACE2 receptor 29 . In order to investigate the cell entry of S-pseudovirus, several ACE2 + cell lines were applied. WB analysis showed that HeLa and HEK293T-ACE2 cells had a high level of ACE2 expression. HCT116 and PC3 cells had a moderate expression level, and SW620 and A549 cells had a minimal level of ACE2 expression (Fig. 3A) . It was also revealed that the cell entry efficiency was closely associated with the ACE2 expression level; for example, the cell entry efficiency of the S-pseudovirus was high in the Hela and HEK293T-ACE2 cells but low in the SW620 and A549 cells. Importantly, the treatment with EVs-ACE2 resulted in the inhibition of the S-pseudovirus to enter the cells, which was reflected by the significant reduction of the pseudovirus-labeled fluorescence ( Fig. 3C and D) . These results demonstrated that EVs-ACE2 efficiently blocked the entry of S-pseudovirus into the cells. The infection efficiency was performed by titrating the S-pseudovirus. After transfection, the co-packed pNL4-3.Luc.RE luciferase was generated. Therefore, luminescence intensity was a transfection indicator. The results showed that the HeLa, HCT116, and PC3 cells were more effectively transduced by the S-pseudovirus than the SW620 and A549 cells, and the highest transduction efficiency (approximately 2 × 10 6 RLU) was observed in the HeLa cells with the highest ACE2 expression, 20-fold higher than the SW620 or A549 cells with the low ACE2 expression (Fig. 3E) . However, the infection efficiency in the cells was decreased by EVs-ACE2 treatment, and Fig. 3E shows that EVs-ACE2 treatment reduces 96% luciferase activity compared to the control group. It was demonstrated that the EVs-ACE2 significantly blocked the S-pseudovirus infection in the Hela, HT116, and PC3 cells with high ACE2 expression. The results suggest that the entry and infection of SARS-CoV-2 were blocked by administering EVs-ACE2 to neutralize the virus. This was also verified by qRT-PCR (Fig. 3F ). In symptomatic and asymptomatic patients, nasal swabs typically have been found to have a higher viral load of SARS-CoV-2 than throat swabs do 30 . Notably, nasal epithelial cells, containing goblet cells and ciliated cells, show high expression of ACE2. This indicates that the nasal cavity is the primary portal and incubator for SARS-CoV-2 to enter the human body 31 . The ACE2 protein was highly expressed in the nasal epithelium of the mice (Fig. 4A) . The S-pseudovirus (red) was successfully captured by the EVs-ACE2 (green) that were intranasally pre-administered to the mice, reflected by the major overlap of the fluorescence of red and green. By contrast, in the EVs-Control group, there was much less overlap of the fluorescence (Fig. 4C ). The overlap proportion was reflected in the Pearson's value: 0.59 (EVs-ACE2 group) vs. 0.04 (EVs-Control group) (Fig. 4B ). In the qRT-PCR assay, we obtained the same conclusions (Fig. 4D) . Furthermore, the epithelium tissues were processed for flow cytometry analysis, which showed that the S-pseudovirus positive rates in the non-treatment and EVs-Control groups were more than 100 times higher than the EVs-ACE2 group (16.2% and 13.1% vs. 0.13%, Fig. 4E ). There are olfactory epithelium and respiratory epithelium in the nasal cavity. Although they have a different biological function, both of them overexpress ACE2 32-J o u r n a l P r e -p r o o f treatment with ACE2-expressing EVs. After intranasal administration of EVs-ACE2, a blood chemistry test was conducted three days later. The results showed no obvious changes, and all remained at the baseline levels (Fig. 5B) . The histopathological analysis also reveals that there was no evidence of lesion or tissue damage (Fig. 5A ). Neutralization strategy plays an important role in antivirus therapy. For example, monoclonal antibodies 35, 36 , antisera 37 , and recombinant human ACE2 protein 38 have also been investigated for neutralization treatment. Among them, the recombinant human ACE2 has been considered a promising therapeutic agent against COVID-19 39 . However, due to its short half-life, the therapeutic success has not been limited. To address this issue, the use of nanocarriers to deliver ACE2 protein was developed to neutralize SARS-CoV-2 40 . In this work, we proposed ACE2-expressing EVs as a means for preventing healthy individuals. Of note, 41% of the people with COVID-19 had reported experiencing a loss of smell 45 . As nasal mucosa is a front-line defense against respiratory infection in the human body, the intranasal administration of therapeutics could be promising in J o u r n a l P r e -p r o o f limiting the spread of COVID-19. Importantly, intranasal dosing can be selfadministrated and the formulation is easy to be given intranasally. It should be mentioned that physical protective equipment might not provide complete protection in the virus-rich indoor environments, as evidenced by the frequently reported cases in medical centers and hospitals. Therefore, to develop an intranasal medicine (e.g., EVs-ACE2) that could provide additional protection is clinically meaningful. We reported a novel antivirus strategy where engineered EVs with decoy receptors as a nanoplatform can act as a safe and effective therapeutic avenue. Data are presented as mean ± SD (n = 3); ns, no significance. Covid-19 coronavirus pandemic Gastrointestinal sequelae 90 days after discharge for COVID-19 6-Month consequences of COVID-19 in patients discharged from hospital: a cohort study Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19 Tocilizumab in hospitalized patients with severe Covid-19 pneumonia CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models Recent insights for the emerging COVID-19: drug discovery, therapeutic options and vaccine development CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2 Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects The biology, function, and applications of exosomes in cancer Exosomes: new molecular targets of diseases Exosomes in cancer nanomedicine and immunotherapy: prospects and challenges Exosomes: from garbage bins to translational medicine Advances in therapeutic applications of extracellular vesicles Big pharma buys into exosomes for drug delivery Isolation and characterization of exosomes from 22 Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2 Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development HEK293 cell line: A vehicle for the expression of recombinant proteins Exosomes serve as nanoparticles to suppress tumor growth and angiogenesis in gastric cancer by delivering hepatocyte growth factor siRNA Ferroptosis is an autophagic cell death process Reprogramming exosomes as nanoscale controllers of cellular immunity Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2 A pneumonia outbreak associated with a new coronavirus of probable bat origin SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes Lung innervation in the eye of a cytokine storm: neuroimmune interactions and COVID-19 Neuromechanisms of SARS-CoV-2: a Review A Review on the neurological manifestations of COVID-19 infection: a mechanistic view The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv 2021 COVID antibody treatments show promise for preventing severe disease Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19 Human recombinant soluble ACE2 in severe COVID-19 Soluble ACE2 as a potential therapy for COVID Cellular nanosponges inhibit SARS-CoV-2 infectivity Exosome-based liquid biopsies in cancer: opportunities and challenges Engineered extracellular vesicle decoy receptor-mediated modulation of the IL6 trans-signalling pathway in muscle Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 spike protein-containing virus Smell and taste dysfunction in patients with COVID-19: a systematic review and meta-analysis We are thankful for the support of National Special Project for Significant Drugs The authors have no conflicts of interest to declare.